 |
|
Standard
| T/CSBME 079-2024 Quality acceptance requirements for clinical used PET/CT positron drugs in lung cancer (English Version) |
|
|
|
|
|
|
|
|
Detail of T/CSBME 079-2024
| Standard No. |
|
| English Name |
|
| Chinese Name |
|
| Chinese Classification |
|
| Professional Classification |
|
| ICS Classification |
|
| Issued by |
|
| Issued on |
|
| Implemented on |
|
| Status |
|
| Superseded by |
|
| Superseded on |
|
| Abolished on |
|
| Superseding |
|
| Language |
|
| File Format |
| Word Count |
| Price(USD) |
|
| Keywords |
|
Introduction of T/CSBME 079-2024
本文件规定了肺癌PET/CT正电子药物临床使用的质量验收要求。
本文件适用于临床医疗机构在肺癌PET/CT诊断前，对购买或合规自制的PET/CT正电子药物进行质量验收。
本文件不强制所有临床医疗机构在肺癌PET/CT诊断前均执行验收流程，但在诊断过程中怀疑因正电子药物质量问题而影响诊断准确性，建议参考本文件对购买或合规自制的PET/CT正电子药物进行药物质量评估和验收。
Contents of T/CSBME 079-2024